Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
421 Leser
Artikel bewerten:
(2)

Starpharma: VIRALEZE Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure

MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model.

VIRALEZE is a broad-spectrum barrier nasal spray, developed by Melbourne biotech company Starpharma, for application in the nasal cavity to help reduce exposure to virus. VIRALEZE is registered in more than 30 countries, including in Europe, and the UK where it is marketed by LloydsPharmacy.

Challenge models are often used in viral diseases to assess the ability of a product to treat or prevent an infection.

In this study, conducted at Scripps Research in the US, 100% of animals treated with VIRALEZE before and after Omicron virus challenge had no detectable virus in lung, trachea, or nasal cavity at up to four days post-challenge.

VIRALEZE was also highly effective even if used only after exposure to virus - animals treated with VIRALEZE only after virus exposure exhibited a >99.999% reduction in viral load in both lung and trachea, compared with saline-treated animals, at day seven. This finding is important because it suggests that even when VIRALEZE is used after exposure to virus (e.g., you forget to use the spray before exposure in a high-risk situation), it has potential to provide significant benefit.

These impressive results for VIRALEZE were in contrast to saline-treated animals, where 100% had high levels of virus detected in lung, trachea, and nasal cavity from as early as two days post-challenge.

Starpharma CEO Dr Jackie Fairley commented:

"Countries around the world are experiencing significant strain in their healthcare systems as a result of Omicron outbreaks. VIRALEZE represents an additional tool for use alongside vaccinations in these challenging times."

These new data provide further in vivo validation that VIRALEZE is highly effective in trapping and blocking virus in the nasal cavity and suggest that VIRALEZE could be used to help protect from infection with respiratory viruses, including multiple SARS-CoV-2 variants, and potentially as post-exposure prophylaxis to reduce severity of viral respiratory disease.

VIRALEZE also has a potential role in future pandemic preparedness given that SPL7013 in VIRALEZE has been shown to highly effectively block a broad spectrum of respiratory viruses, including pandemic-causing viruses, such as multiple variants of SARS-CoV-2, SARS-CoV, MERS-CoV, influenza A and B , and respiratory syncytial virus (RSV) in vitro.

For more information, visit www.starpharma.com

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.